Drug Profile
Pembrolizumab biosimilar - PlantForm Corporation/Bio-Manguinhos/Fiocruz
Latest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator PlantForm Corporation
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Mar 2023 PlantForm Corporation announces intention to launch Pembrolizumab biosimilar for cancer in Brazil in 2028 (Plantform Corporation Pipeline, March 2023)
- 07 Mar 2023 PlantForm Corporation and Bio-Manguinhos/Fiocruz agree to co-promote [and co-develop] Pembrolizumab biosimilar and up to five future products for the Brazilian and other world markets for Cancer
- 09 Apr 2021 Early research in Cancer in Brazil (Parenteral) prior to April 2021